^
Association details:
| Biomarker: | MSI-H/dMMR |
|---|---|
| Cancer: | Colorectal Adenocarcinoma |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) + Yervoy (ipilimumab) (CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Title:
Opdivo® Intravenous Infusion Approved in South Korea for Two Adjuvant Treatments and Three Combination Treatments
Excerpt:
Ono Pharmaceutical Co...announced that Ono Pharma Korea Co., Ltd. (“OPKR”), a South Korean subsidiary of ONO, received the following approvals of Opdivo (nivolumab) Intravenous Infusion ("Opdivo"), a human anti-human PD-1 monoclonal antibody, on February 14 from the Ministry of Food and Drug Safety (MFDS) in South Korea for two adjuvant treatments and for three combination treatments...In combination with ipilimumab, in adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.
Source:
Title:
Optimal combination dosing schedule of nivolumab and ipilimumab in patients with dMMR and/or MSI metastatic colorectal cancer
Excerpt:
...dMMR and/or MSI tumor status defined by:- Loss of MMR protein expression using immunohistochemistry with two (anti-MLH1 and anti-MSH2 or anti-MSH6, and anti-PMS2) or four (anti-MLH1, anti-MSH2, anti-MSH6, and anti-PMS2) antibodies, - and/or ≥ two instable markers by pentaplex polymerase chain reaction (BAT-25, BAT-26, NR-21, NR-24, and NR-27),NB: Agreement of the Sponsor (GERCOR) is mandatory to include the patient (the patient’s file will be verified to confirm MSI/dMMR status before inclusion [an anonymized fax] and confirmation of a patient’s allocation will be sent by mail to the Investigator within 24h), 8. ...
Trial ID:
Source:
Title:
Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer
Excerpt:
...- Patient must have MSI-H (microsatellite instability-high) or dMMR (deficient mismatch repair) tumors based on immunohistochemistry or PCR (polymerase chain reaction)...
Trial ID:
More C2 evidence
Source:
Title:
Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC.
Excerpt:
...Deficient mismatch repair (dMMR) and/or Microsatellite instability (MSI) tumor status defined by:...
Trial ID:
Source:
Title:
iRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and Ipilimumab
Excerpt:
...dMMR DNA (protein expression by ICH and/or MSI by PCR):...
Trial ID:
Source:
Title:
Nivolumab and Ipilimumab in Patients With dMMR and/or MSI Metastatic Colorectal Cancer Resistant to Anti-PD1 Monotherapy
Excerpt:
...dMMR and/or...
Trial ID:
Source:
Title:
RECIST 1.1 and iRECIST evaluation for patients with deficient MMR and/or MSI Metastatic Colorectal Cancer treated with nivolumab and ipilimumab.
Excerpt:
...GERCOR will check every patient’s file to confirm the dMMR/ MSI-H patient’s status before inclusion (an anonymized fax or scan document in electronic case report form [e-CRF]). ...
Trial ID:
Less C2 evidence
Source:
Title:
Immunotherapy in synchronous MSI-H rectal adenocarcinoma and upper tract urothelial carcinoma: a case report
Published date:
02/22/2022
Excerpt:
Here we present a case of a middle-aged woman diagnosed with dMMR/MSI-H locally advanced rectal cancer with synchronous upper tract urothelial cancer secondary to Lynch syndrome. The patient was first treated using neoadjuvant chemotherapy followed by chemoradiation, resulting in only a partial pathologic response. Following surgery, the patient was treated with adjuvant combination immunotherapy with nivolumab, a PD-1 inhibitor, and ipilimumab, a CTLA-4 inhibitor, resulting in a durable disease-free interval of nearly 21 months.
DOI:
10.21037/jgo-22-81
